The Jackson Laboratory in Bar Harbor, Maine, with a team comprised of University of Connecticut Health Center, New York Stem Cell Foundation, InSilico Trials Technologies, and University of Michigan, intends to replicate broad human cardiovascular variation to comprehensively characterize non-arrhythmic cardiotoxicity using transcriptomic, metabolic, and phenotypic analyses. By building digital cardio models based on mouse and human physiology, drugs can be evaluated against a wide range of heart genetic profiles and physiology differences based on patient populations.